Dr. Bertalan Mesko discusses the role of artificial intelligence in the future of health care, how patients are driving adoption – and the seemingly thin line between “healing” and “upgrading.”

Outsourcing-Pharma Podcast

A discussion with The Medical Futurist: AI to take health care 'to the next level’

Changing pills to a more user-friendly formulation can increase patient compliance, brand loyalty, and extend IP exclusivity, says CMO Hermes in an exclusive podcast.

A bitter pill to swallow: young people dislike tablets more than old

Kemwell CEO Agneta Bergvall says drugmakers&#039; efforts to make pharmaceutical manufacturing green are worth the cost.

Kemwell CEO says environmental efforts are worth the cost

Catalent has announced two new softgel solutions as it adds greater versatility to its Advanced Technologies Business Unit.

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

In the war against counterfeits, regulators have concentrated on serialisation and ePedigree and missed an opportunity on product authentication, according to AlpVision.

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Risk-based monitoring for clinical trials was a hot topic at this year’s PCT Europe thanks to recent draft guidances from the FDA and the EMA.

Is risk-based clinical trial monitoring too flexible for the regulators?

CMO Cobra Biologics says North America is an obvious place to look at for a facility acquisition.

Cobra Biologics talks recent fill finish acquisition and future growth plans

Catalent says making its technology available to industry will not affect its competitive edge.

Catalent says sharing with industry will not dull competetive edge

Bend Research is “actively” hunting new partnerships similar to its recent alliance with Dow.

Bend Research hunting new partnerships to boost bioavailability offering

The proposed changes to European clinical trial regulations accepted by the European Commission (EC) in July will put Europe on an equal playing field, according to Clinipace’s Andrea Schiefer.

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Negotiating funding for drugs with local health authorities prior to commercialisation is the key to success for biopharmas working in the changing European market, says Quintiles.

Overhaul of EU health systems good opportunity for outcomes data providers, says Quintiles

The use of home visits in clinical trials could raise the chances of regulatory approval, according to ResearchNurses.co.

Home visits = regulatory thumbs up? ResearchNurses.co thinks so

Including home visits in clinical trial designs could be the key to patient retention, according to ResearchNurses.co.

Home visits are the key to patient retention, says ResearchNurses.co

‘CROs: look at the entire portfolio, not just the individual project, when planning clinical studies,’ says DIA’s adaptive design scientific working group.

R&D and commercial work together to design trials, says DIA

SGS has added formulation development to its service offering through the expansion of its laboratory in Illinois.